Capital Cell is Europe's first online investment platform specialising in biomedicine. Despite the global coronavirus pandemic, it has raised 4 million euros of investment for 4 companies in the first quarter of 2020. The coronavirus crisis is hitting the global economy hard, especially in our country.
After a tough quarter for the markets, investment funds have opted to bet on biomedical high-tech companies, a sector in full bloom in Spain. This is the case of Cell Capital.
Biotechnology, the only sector to be spared
According to Capital Cell CEO Daniel Oliver"In a context such as the current one, the importance of biotechnology goes from being strategic to being urgent, and it is going to establish itself as one of the most desirable investment sectors". The investment made by Capital Cell alone would represent more than 12% of the total investment made in the biotechnology sector in Spain in 2018, which amounted to €98 million according to the Spanish Association of Biotechnology Companies.
No obstante, no sólo España registra un crecimiento de la inversión en biotecnología. Entre febrero y marzo, el sector biotecnológico ha supuesto la inversión con mayor rentabilidad del índice NASDAQ estadounidense, mientras la mayoría de los sectores de inversión, incluyendo el financiero, la energía o el inmobiliario, registran desplomes históricos.
Capital Cell doesn't miss a beat
The online investment platform specialising in biomedicine invested four million euros in four companies in the biotech sector in the first quarter of this year, which is 37% more than in the same period last year. It is also more than a third of the total invested last year, as €11.6m was moved in 2019.
For example, since the start of the Covid-19 crisis confinement, Capital Cell has successfully launched and closed a ¤560,000 investment round for Valencian digital diagnostic system companyeKuore. Also other start-ups such asAortyx,DevicareoAbility Pharma6 million have been confirmed.
